UB congratulates 43North finalists

Winners include Cytocybernetics, a biotechnology firm founded by two UB professors

“This exciting new program has once again spotlighted the startup culture that is flourishing in Buffalo. It is attracting talented entrepreneurs from across the world and helping to plant the seeds for tremendous economic growth in the years to come.”

Satish K. Tripathi, president

University at Buffalo

BUFFALO, N.Y. – “It is my great pleasure to
congratulate all the finalists in the 43North business idea
competition, especially Cytocybernetics, a remarkable biotechnology
firm founded by UB professors Glenna Bett and Randall
Rasmusson,” said UB President Satish K. Tripathi.

UB is very proud of the leadership role its faculty members,
researchers and graduates play in helping to solve critical and
emerging problems that society faces, as well as their work that
leads to sustained, long-term economic growth in Western New York,
Tripathi said.

“This exciting new program has once again spotlighted
the startup culture that is flourishing in Buffalo. It is
attracting talented entrepreneurs from across the world and helping
to plant the seeds for tremendous economic growth in the years to
come.”

Interim Vice President for Research and Economic Development
Venu Govindaraju said: “It’s entrepreneurs like Glenna
Bett and Randall Rasmusson that are solidifying Western New
York’s reputation as a world-class research hub for
biotechnology and life sciences. Extraordinary technologies, such
as Cytocybernetics’ technique for replicating heart cells,
are at the forefront of the Buffalo Niagara region’s economic
resurgence. UB is looking forward to continuing to work with
Cytocybernetics to help ensure that it becomes a cornerstone in
Western New York’s economy.”

UB has partnered with Cytocybernetics through its Office of
Science, Technology Transfer and Economic Outreach; the Center for
Advanced Biomedical and Bioengineering Technology; UB’s New
York State Center in Excellence in Bioinformatics and Life Sciences
and START-UP NY. Cytocybernetics also received a $50,000 investment
from the State University of New York Technology Accelerator
Fund.